Celgene aims to block a generic of blood cancer treatment Revlimid

08/25/2010 | Wall Street Journal, The

Celgene plans to "enforce its extensive intellectual property rights" on multiple myeloma drug Revlimid after an unnamed drugmaker filed for FDA approval of a generic version. The treatment is covered by 12 patents, with expiration as far out as 2026. Celgene has not received formal notice of the generic challenge.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC